Adding PD1 Inhibitor to Neoadjuvant Chemotherapy Significantly Increases the pCR Rate in High-Risk, Early-Stage ER-positive, HER2-negative Breast Cancer By Ogkologos - February 12, 2025 158 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 7FL and KEYNOTE-756 studies Source RELATED ARTICLESMORE FROM AUTHOR Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer MOST POPULAR No Benefit for Post-operative Radiotherapy in Non-small-cell Lung Cancer [ESMO2020 Press... September 20, 2020 For Women With Dense Breasts, An MRI May Be A Better... November 29, 2019 New on NCI’s Websites for June 2020 June 26, 2020 Time to meet our new chief scientist – Professor KJ Patel October 12, 2022 Load more HOT NEWS Encouraging Single-Agent Antitumour Activity of Divarasib Across KRAS G12C-positive Tumours PSMA PET-CT Accurately Detects Prostate Cancer Spread, Trial Shows Crazy Bride Called Off Her Wedding Because Her Guests Refused To... Intratumoural and Intracavitary Administration of Ipilimumab Plus Nivolumab Is Feasible and...
